Active substance
Deflazacort
- SFDA 2
- US FDA 14
- NHS prices 1
- Safety 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Disflax | 30 mg | Tablet · Oral use | 10 Blister | SAR 28.50 | Generic · Prescription | FAES FARMA, S.A. | Valid |
| Disflax | 6 mg | Tablet · Oral use | 20 Blister | SAR 11.40 | Generic · Prescription | FAES FARMA, S.A. | Valid |
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| EMFLAZA | 6MG; 18MG; 30MG; 36MG | tablet · oral | PTC THERAP | Prescription | 9 Feb 2017 |
| EMFLAZA | 22.75MG/ML | suspension · oral | PTC THERAP | Prescription | 9 Feb 2017 |
| DEFLAZACORT | 6MG; 18MG; 30MG; 36MG | tablet · oral | AUROBINDO PHARMA LTD | Prescription | 9 Feb 2024 |
| DEFLAZACORT | 22.75MG/ML | suspension · oral | TRIS PHARMA INC | Prescription | 25 Apr 2024 |
| DEFLAZACORT | 6MG; 18MG; 30MG; 36MG | tablet · oral | UPSHER SMITH LABS | Prescription | 5 Nov 2024 |
| DEFLAZACORT | 6MG; 18MG; 30MG; 36MG | tablet · oral | SUN PHARM | Prescription | 18 Mar 2025 |
| JAYTHARI | 6MG; 18MG; 30MG; 36MG | tablet · oral | ZYDUS LIFESCIENCES | Prescription | 8 Apr 2025 |
| PYQUVI | 22.75MG/ML | suspension · oral | AUCTA | Prescription | 30 Jun 2025 |
| DEFLAZACORT | 22.75MG/ML | suspension · oral | UPSHER SMITH LABS | Prescription | 11 Aug 2025 |
| DEFLAZACORT | 22.75MG/ML | suspension · oral | ZYDUS LIFESCIENCES | Prescription | 3 Oct 2025 |
| DEFLAZACORT | 6MG; 18MG; 30MG; 36MG | tablet · oral | AMNEAL | Prescription | 12 Dec 2025 |
| DEFLAZACORT | 22.75MG/ML | suspension · oral | SUN PHARM INDS INC | Prescription | 27 Jan 2026 |
| DEFLAZACORT | 22.75MG/ML | suspension · oral | BIOCON PHARMA | Prescription | 28 May 2026 |
| DEFLAZACORT | 6MG; 18MG; 30MG; 36MG | tablet · oral | HIKMA PHARMS | Prescription | 18 Sep 2026 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Deflazacort 6mg tablets | £15.82 | 60 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 5 Jun 2024 EMFLAZA — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 5 Jun 2024 EMFLAZA — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.